• Je něco špatně v tomto záznamu ?

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy

Z. Zděblová Čermáková, P. Hurník, D. Konvalinka, J. Štembírek, T. Paračková, K. Resová, J. Cvek, T. Blažek, L. Knybel, M. Formánek, M. Gachechiladze, M. Joerger, A. Soltermann, J. Škarda, O. Motyka, J. Janoutová

. 2023 ; 59 (2) : . [pub] 20230214

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004172

INTRODUCTION: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. OBJECTIVE: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. METHOD: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. RESULTS: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. CONCLUSION: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004172
003      
CZ-PrNML
005      
20240111103510.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/medicina59020361 $2 doi
035    __
$a (PubMed)36837562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zděblová Čermáková, Zuzana $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic $1 https://orcid.org/0000000286683732
245    10
$a HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy / $c Z. Zděblová Čermáková, P. Hurník, D. Konvalinka, J. Štembírek, T. Paračková, K. Resová, J. Cvek, T. Blažek, L. Knybel, M. Formánek, M. Gachechiladze, M. Joerger, A. Soltermann, J. Škarda, O. Motyka, J. Janoutová
520    9_
$a INTRODUCTION: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. OBJECTIVE: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. METHOD: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. RESULTS: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. CONCLUSION: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
650    _2
$a lidé $7 D006801
650    _2
$a prognóza $7 D011379
650    12
$a infekce papilomavirem $x komplikace $7 D030361
650    12
$a spinocelulární karcinom $x patologie $7 D002294
650    12
$a nádory orofaryngu $7 D009959
650    _2
$a rekombinasa Rad51 $7 D051135
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hurník, Pavel $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology and Medical Gentics, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine, Masaryk University Brno, 625 00 Brno, Czech Republic
700    1_
$a Konvalinka, David $u EUC Laboratory CGB, Inc., 703 00 Ostrava, Czech Republic $7 xx0312628
700    1_
$a Štembírek, Jan $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic $u Department of Oral and Maxillofacial Surgery, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic
700    1_
$a Paračková, Tereza $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Resová, Kamila $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000206569084
700    1_
$a Cvek, Jakub $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic
700    1_
$a Blažek, Tomáš $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Third Faculty of Medicine, Charles University Prague, 100 00 Prague, Czech Republic
700    1_
$a Knybel, Lukáš $u Department of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000224616606
700    1_
$a Formánek, Martin $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000257592073
700    1_
$a Gachechiladze, Mariam $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Joerger, Markus $u Department of Medical Hematology and Oncology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland
700    1_
$a Soltermann, Alex $u Facharzt Foederatio Medicorum Helveticorum (FMH) Pathologie, Pathologie Längasse, 3063 Ittingen, Switzerland
700    1_
$a Škarda, Jozef $u Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology and Medical Gentics, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Motyka, Oldřich $u Faculty of Mining and Geology, VŠB-Technical University of Ostrava, 708 33 Ostrava-Poruba, Czech Republic $u Nanotechnology Centre, VŠB-Technical University of Ostrava, Nanotechnology Centre, 708 33 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000296440611 $7 xx0228211
700    1_
$a Janoutová, Jana $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
773    0_
$w MED00180386 $t Medicina $x 1648-9144 $g Roč. 59, č. 2 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36837562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20240111103505 $b ABA008
999    __
$a ok $b bmc $g 1924688 $s 1190381
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 59 $c 2 $e 20230214 $i 1648-9144 $m Medicina $n Medicina (Kaunas) $x MED00180386
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace